Back to Research Hub
ORIC Pharmaceuticals, Inc.
ORIC
$10.89-0.02 (-0.21%)
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates.
StreetsValue research for ORIC Pharmaceuticals, Inc. (ORIC)
Members get the full report for ORIC Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.